# Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
- Published: 2026-11-13
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/vericel-to-present-at-the-stephens-annual-investment-conference-on-wednesday-november-18-2/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/
BURLINGTON, Mass., Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
**About Vericel Corporation**
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.
Epicel®, MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.
**Investor Contact:
**Eric Burns
ir@vcel.com
+1 (734) 418-4411
## Related
- [Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026](https://healthcarenews.io/news/wave-life-sciences-highlights-wve-007-inhbe-sirna-progress-at-obesityweek-2026.md)
- [Kyntra Bio to Report Third Quarter 2026 Financial Results](https://healthcarenews.io/news/kyntra-bio-to-report-third-quarter-2026-financial-results.md)
- [SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion](https://healthcarenews.io/news/ss-innovations-strengthens-management-team-in-preparation-for-global-sales-expansion.md)
- [AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results](https://healthcarenews.io/news/aim-immunotech-approaches-major-clinical-inflection-point-with-phase-2-pancreatic-cancer-d.md)